SOHO 2021 | Up-and-coming therapies: talquetamab & cevostamab
Maria-Victoria Mateos, MD, PhD, of the University of Salamanca, Salamanca, Spain, outlines the use of the latest therapeutic agents talquetamab and cevostamab, as well as giving insight into how these drugs will integrate into the myeloma treatment algorithm. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Transcript (edited for clarity)
And cevostamab, these specific monoclonal antibodies targeting two specific antigens expressed on the surface of the plasma cell. Talquetamab targets GPRC5D and cevostamab targets FcRH5. These monoclonal antibodies have reported great efficacy and safety data, with anti-CD38 monoclonal antibodies. But I would like to remark that these two bi-specific monoclonal antibodies have been evaluated also in patients previously exposed to BCMA-targeted therapy, and the response is maintained in this subgroup of patients...
And cevostamab, these specific monoclonal antibodies targeting two specific antigens expressed on the surface of the plasma cell. Talquetamab targets GPRC5D and cevostamab targets FcRH5. These monoclonal antibodies have reported great efficacy and safety data, with anti-CD38 monoclonal antibodies. But I would like to remark that these two bi-specific monoclonal antibodies have been evaluated also in patients previously exposed to BCMA-targeted therapy, and the response is maintained in this subgroup of patients. So from my point-of-view, these two different monoclonal antibodies, bi-specific but targeting antigens different to BCMA, will give us the opportunity to utilize them, maybe after previous exposition to BCMA-targeted therapy.
Read more...
Disclosures
Maria-Victoria Mateos, MD, PhD, has received honoraria from lectures and participated in boards with Janssen, BMS-Celgene, AbbVie, Amgen, Takeda, GSK, Sanofi, Oncopeptides, Pfizer, Regeneron, Adaptive, Roche, Bluebird-bio and Sea-Gen.
